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Pax3 and Pax7 play distinct but overlapping
roles in developmental and postnatal myogene-
sis. The mechanisms involved in the differential
regulation of these highly homologous proteins
are unknown. We present evidence that Pax3,
but not Pax7, is regulated by ubiquitination and
proteasomal degradation during adult muscle
stem cell activation. Intriguingly, only monoubi-
quitinated forms of Pax3 could be detected.
Mutation of two specific lysine residues in the
C-terminal region of Pax3 reduced the extent
of its monoubiquitination and susceptibility to
proteasomal degradation, whereas introduc-
tion of a key lysine into the C-terminal region
of Pax7 rendered that protein susceptible to
monoubiquitination and proteasomal degrada-
tion. Monoubiquitinated Pax3 was shuttled to
the intrinsic proteasomal protein S5a by inter-
acting specifically with the ubiquitin-binding
protein Rad23B. Functionally, sustained ex-
pression of Pax3 proteins inhibited myogenic
differentiation, demonstrating that Pax3 degra-
dation is an essential step for the progression
of the myogenic program. These results reveal
an important mechanism of Pax3 regulation
in muscle progenitors and an unrecognized
role of protein monoubiquitination in mediating
proteasomal degradation.
INTRODUCTION
Pax3 is a key regulator of myogenesis during development
(Buckingham et al., 2003). In splotch (Sp) mice, which
carry spontaneous mutations in the pax3 locus, limb
muscles are absent (Bober et al., 1994). The formation of
these muscles requires Pax3, which has been shown to
induce the expression of c-Met, a tyrosine kinase receptor
essential for the delamination and migration of muscleprogenitor cells (Bladt et al., 1995; Yang et al., 1996).
More recently, it was shown that Pax3 and its close homo-
log, Pax7, are expressed in a population of myogenic pre-
cursor cells that give rise to a population of adult muscle
stem cells (Gros et al., 2005; Relaix et al., 2005). Interest-
ingly, cells that fail to express Pax3 or Pax7 die or switch to
another cell fate (Relaix et al., 2005).
In postnatal myogenesis, Pax3 is transiently expressed
during muscle stem cell (‘‘satellite cell’’) activation in
a highly proliferative intermediate progenitor cell popula-
tion (Conboy and Rando, 2002). The association of
enhanced Pax3 activity with a highly proliferative state is
consistent with aberrant Pax3 expression with tumors
bearing skeletal muscle characteristics (Barr, 2001). In
humans, a severe form of alveolar rhabdomyosarcoma
(ARMS) is due to a chromosomal translocation t(2; 13)
that results in a fusion between the Pax3 gene and the
forkhead (FKHR) gene and the generation of a Pax3FKHR
fusion protein. This protein consists of the DNA-binding
domains of Pax3 fused to the transcription activation do-
main of FKHR. Pax3FKHR is a powerful gain-of-function
mutation (Bennicelli et al., 1999) and is thought to exert
its role in ARMS through aberrant regulation of Pax3 target
genes (Barr, 2001).
It is clear that normal muscle development and
postnatal myogenesis depend on the timely and coordi-
nated expression of Pax3 and Pax7. In the present
study, we investigated the regulation of Pax3 and Pax7
at the protein level, based on evidence of differential
responses to inhibition of proteasomal activity. The data
presented support the hypothesis that the levels of Pax3,
but not Pax7, are regulated by the ubiquitin/proteasome
pathway. In addition, the results suggest a unique mech-
anism of proteasomal degradation involving protein
monoubiquitination.
RESULTS
Proteasome-Mediated Degradation of Pax3
during Postnatal Myogenesis
Pax3 protein and transcript were expressed transiently
during satellite cell activation (Figures 1A–1C), consistentCell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 349
Figure 1. Pax3 Is Regulated at the Pro-
tein Level during Postnatal Myogenesis
(A) Analysis of Pax3 protein by flow cytometry
in satellite cells 0, 1, 2, 3, 4, and 7 days after
activation and in long-term (LT) primary myo-
blast cultures.
Error bars represent ± SD.
(B) Single fibers were isolated and plated on
1:10 ECM for 2 days then fixed and immuno-
stained for Pax3 and MyoD (nuclei are stained
blue with DAPI). Satellite cells still associated
with the fiber and those migrating away from
the fiber were almost all MyoD+. Some of these
were Pax3+ (arrows) and others were Pax3
(arrowheads).
(C) Quantitative analysis of Pax3 mRNA level at
days 0, 1, 2, 3, 4, and 7 relative to the maximal
expression level (day 3) and normalized to Actin
and 18S ribosomal RNA in satellite cells, in
long-term (LT) primary myoblast cultures, and
in myoblasts induced to undergo differentiation
in differentiation medium (DM) for 1 or 2 days,
as indicated. Error bars represent ± SD.
(D) The percentage of Pax3+ cells was analyzed
by flow cytometry in satellite cell progeny after
5 days in culture and then 24 hr in either control
medium or medium containing MG132. Error
bars represent ± SD.
(E) Western blot analysis of Pax3 expression in
myoblasts (quantitation of replicate experi-
ments shown on the right). Myoblasts in growth
medium were treated for 6 hr with control me-
dium or medium containing different doses of
MG132. Error bars represent ± SD.with previous findings (Conboy and Rando, 2002). The
percentage of Pax3+ myogenic progenitors was almost
zero initially but increased rapidly, peaking around day 3
(Figures 1A and 1B), thus paralleling the appearance of
intermediate progenitor cells (Conboy and Rando, 2002).
Pax3 protein then declined to undetectable levels as
progenitor cells proliferated and progressed along the
myogenic lineage pathway (Figure 1A). In established
myoblast cultures, Pax3+ cells were rare (Figure 1A).
Quantitative RT-PCR analysis showed that Pax3 tran-
script was nearly undetectable in quiescent satellite cells
from hindlimb muscle but was highly induced during satel-
lite cell activation, peaking around day 3. Transcript levels
then declined but were maintained at intermediate levels
thereafter, even as protein levels declined further (Figures
1A and 1C). Only when myogenic progenitors were in-
duced to differentiate did the levels of Pax3 transcript
fall to undetectable levels (Figure 1C). Clearly, a marked
discrepancy exists between the levels of Pax3 mRNA
and protein during the late stages of the myogenic350 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.program, suggesting that Pax3 protein level is regulated
posttranscriptionally.
To test for the role of protein degradation in regulating
levels of Pax3, we treated cultures of activated satellite
cells with the proteasome inhibitor, MG132. This resulted
in a more than 3-fold increase in the percentage of Pax3+
cells (Figure 1D). Likewise, treatment of myoblast cultures
with MG132 resulted in a dose-dependent increase in
Pax3 protein level but no change in the level of Pax7
(Figure 1E). These results suggest that the decline in
Pax3 protein levels during myogenic lineage progression,
when Pax7 levels are maintained, is due to selective deg-
radation of Pax3 by the ubiquitin/proteasome system
(UPS).
Pax3 Degradation Requires a Functional UPS
To confirm that the degradation of Pax3 was due to the
UPS, we used the ts20b cell line, which carries a tempera-
ture-sensitive ubiquitin-activating enzyme, E1 (Chowdary
et al., 1994). Pax3 levels were stable at a nonpermissive
Figure 2. Noncanonical Ubiquitin-Mediated Proteasomal Degradation of Pax3 In Vitro
For (A) and (B), representative results are presented above and quantitative analyses of replicate experiments are shown below.
(A) In a cell-free-coupled ubiquitination/degradation assay, analysis of degradation of 35S-labeled Pax7 and Pax3 was carried out in absence of 26S
proteasome (Control), in presence of 26S proteasome with Ub (+26S), or in presence of 26S proteasome with Ub and MG132 (+MG132). Protein levels
were assessed by SDS-PAGE followed by autoradiography. Error bars represent ± SD.
(B) Reactions containing forms of ubiquitin that precluded polyubiquitination (methylated ubiquitin [+UbMe] or ubiquitin with no lysines [+UbK0])
revealed degradation of Pax3. When the reactions were carried out in the presence of MG132, the degradation of Pax3 was inhibited in the presence
of UbMe (+UbMe +MG132) and UbK0 (+UbK0 +MG132). Error bars represent ± SD.
(C) In a cell-free ubiquitination assay, ubiquitination of 35S-labeled Pax3 or p21CIP1 was carried out in presence of MG132 and either Ub or UbK0. The
left panel shows that only monoubiquitinated Pax3 was generated even in the presence of WT Ub, whereas polyubiquitinated forms of p21CIP1 were
clearly generated. As expected, only monoubiquitinated forms of both proteins were detected in the presence of UbK0. Arrows indicate the positions
of the native proteins (Pax3 and p21), monoubiquitinated forms (Pax3-Ub1 and p21-Ub1), and polyubiquitinated forms (Pax3-Ubn and p21-Ubn).
(D) Ubiquitination of 35S-labeled Pax3 was carried out in the presence of a reaction solution containing 26S proteasome that had been pretreated with
either Ub or UbK0 (both His-tagged) but in the absence of MG132. The proteins were subjected to Nickel-agarose purification. Less monoubiquiti-
nated Pax3 was generated when the reaction mixture was pretreated with WT ubiquitin. Native Pax3 is not present because it is not pulled down
by the Nickel-agarose purification. The graph on the right represents the quantitation of monoubiquitinated Pax3 protein normalized to the amount
of monoubiquitinated Pax3 protein in reactions pretreated with UbK0.
(E) The stability of recombinant Pax3 was assessed for 6 or 18 hr in an excess of Ub in a reaction solution containing 26S proteasome that had been
pretreated with either Ub or UbK0. The amount of Pax3 proteins remaining was determined by immunoblot analysis.temperature but declined at a permissive temperature
(Figure S1). The control cell line (H38-5) demonstrated
Pax3 degradation regardless of the temperature (Fig-
ure S1). These data show that Pax3 degradation requires
a functional UPS.
In Vitro Evidence of UPS-Mediated Degradation
of Monoubiquitinated Pax3
To test directly if Pax3 is susceptible to proteasomal deg-
radation, we used a cell-free ubiquitination/proteasome
degradation assay (Bloom et al., 2003). Under a standardcondition in which p21CIP1 that was used as a positive
control (Bloom et al., 2003) was rapidly degraded
(Figure S2), Pax7 was stable (Figure 2A), as predicted
from the in vivo results (Figure 1E). However, in apparent
contradiction of the previous results in vivo (Figures 1
and S1), Pax3 was unexpectedly stable (Figure 2A). This
apparent paradox of the MG132-sensitive and E1-ligase-
dependent degradation of Pax3 in vivo with its apparent
stability in vitro was resolved when the in vitro assays
were carried out in the presence of either methylated ubiq-
uitin (UbMe) or mutant ubiquitin containing no lysinesCell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 351
(UbK0), both of which allow monoubiquitination but
prevent polyubiquitination (Chau et al., 1989; Hershko
et al., 1991). Under these conditions, Pax3, but not
Pax7, underwent rapid proteasomal degradation (Figures
2B and S3A). Furthermore, this degradation was inhibited
by MG132 (Figure 2B). Therefore, in vitro conditions in
which protein ubiquitination is limited to monoubiquitina-
tion closely resembled the in vivo situation in which
Pax3, but not Pax7, was susceptible to proteasome-
mediated degradation. These findings suggest that one
or more components of the assay system that are respon-
sible for ubiquitination and/or degradation of Pax3 may
themselves undergo polyubiquitination and degradation
in the presence of wild-type (WT) ubiquitin. These results
also suggest that a monoubiquitinated form of Pax3 may
be susceptible to proteasome-mediated degradation,
contrary to the canonical views of the consequences of
protein monoubiquitination and the necessity of proteins
to be polyubiquitinated to be susceptible to proteasomal
degradation.
To examine Pax3 ubiquitination patterns, we sought to
uncouple ubiquitination from proteasomal degradation.
We included MG132 throughout the experiment in order
to allow ubiquitination to progress but prevent any protea-
somal degradation. Under those conditions, Pax3 was
monoubiquitinated whether the reaction was carried out
in the presence of UbK0 (as expected) or WT ubiquitin
(Ub) (Figure 2C). These assay conditions resulted in poly-
ubiquitination of p21CIP1 in the presence of Ub, showing
that all components necessary for polyubiquitination
were present (Figure 2C). Even after purification by
Nickel-agarose beads to pull down all ubiquitinated forms
of Pax3, only a monoubiquitinated Pax3 was apparent
(Figure S4).
We then tested directly our hypothesis that a component
of the assay system is both responsible for Pax3 ubiquiti-
nation and itself susceptible to ubiquitination and protea-
somal degradation. We tested this by comparing Pax3
ubiquitination under two conditions. First, we pretreated
the ubiquitin ligase fraction with Ub but in the absence
of MG132, thus allowing for degradation of any polyubi-
quitinated proteins generated. Then, for comparison, we
pretreated the ubiquitin ligase fraction with UbK0 to
prevent any polyubiquitination of assay components that
might then be degraded by the 26S proteasome. Under
these two conditions, subsequent addition of Pax3 protein
(in the presence of MG132 to prevent degradation of ubiq-
uitinated Pax3) revealed that Pax3 monoubiquitination
was enhanced when the reaction components were
protected by UbK0 compared to that seen when the ubiq-
uitin ligase fraction was pretreated with Ub (Figure 2D).
Furthermore, when reactions were carried out under con-
ditions that permitted the formation of only monoubiquiti-
nated Pax3 but allowed for proteasomal degradation,
there was a rapid decline in Pax3 levels (Figure 2E). These
results again suggest that our in vitro assay most closely
parallels the in vivo conditions when components of the
in vitro assay are protected against polyubiquitination352 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.and degradation. Together, the results strongly suggest
that Pax3 undergoes primarily, if not exclusively,
monoubiquitination and that, surprisingly, the monoubi-
quitinated form of Pax3 is the form targeted for proteaso-
mal degradation.
Lysines 475 and 437 Are Important
for the Ubiquitination and Degradation of Pax3
To study further the ubiquitination of Pax3, we sought to
identify the lysines in the protein that were targets for
ubiquitination. Our first clues came from differential sus-
ceptibilities to proteasomal degradation of proteins with
high homology to Pax3. We compared stabilities of
Pax3, Pax7, and Pax3FKHR in pulse-chase experiments
in myoblasts (Figure 3A). In Pax3FKHR, the C-terminal
region of Pax3 is replaced by the C-terminal region of
FKHR. While Pax3 degradation was inhibited by MG132,
Pax3FKHR protein stability was not affected by the inhib-
itor, consistent with the resistance of Pax3FKHR to degra-
dation in the cell-free assay even in the presence of UbMe
(Figure S3B). Since FKHR itself does not confer protein
stability (Matsuzaki et al., 2003), this result suggests that
the region of Pax3 missing from the fusion protein may
contain an important ubiquitination site required for the
degradation of Pax3. Pax7 was not susceptible to protea-
somal degradation in these pulse-chase experiments
(Figure 3A). We thus focused our attention on lysines in
the C-terminal region of Pax3 (Figure 3B). Within this
region, there is one lysine (lysine 475) specific to Pax3
and another (lysine 437) present in both Pax3 and Pax7
(Figure 3B). Replacement of lysine 475 with arginine (mu-
tant termed Pax3SM) dramatically reduced the degrada-
tion of Pax3 in myoblasts (Figure 3C). A double mutant
(Pax3DM) in which both lysine 475 and lysine 437 were
replaced by arginines stabilized Pax3 even further
(Figure 3C). These results suggest that these two lysines
are important for the ubiquitination of Pax3 and for its
subsequent degradation, even though lysine 437 does
not render Pax7 susceptible to these processes.
Pax3 Monoubiquitination Level Correlates with Pax3
Degradation Rate in Myoblasts
Since Pax3 protein became more stable by the mutation
of lysines 475 and 437, we assessed the ubiquitination
status of Pax3, Pax3SM, and Pax3DM in myoblasts. West-
ern blot analysis of the immunoprecipitated Pax3 proteins
was conducted with an antibody (FK-1) that recognizes
only polyubiquitinated proteins or an antibody (FK-2)
that recognizes both mono- and polyubiquitinated pro-
teins (Fujimuro et al., 1994). No polyubiquitinated conju-
gates of any of these proteins were detected with FK-1
(Figure 4A). With FK-2, bands corresponding in molecular
weight to monoubiquitinated conjugates of each protein
were observed. There was less monoubiquitinated
Pax3SM than monoubiquitinated Pax3, and still less mono-
ubiquitinated Pax3DM (Figure 4A). Therefore, mutating
these specific C-terminal lysine residues did not abrogate
completely the ubiquitination of Pax3, but the relative
Figure 3. Degradation of Pax Proteins in Myoblasts
For (A) and (C), representative results are presented above and quantitative analyses of replicate experiments are shown below.
(A) Analysis of Pax7, Pax3, and Pax3FKHR protein stability by pulse-chase experiments in myoblasts. Myoblasts were transfected with constructs
expressing Pax7, Pax3, or Pax3FKHR together with DsRed expression constructs. The cells were treated with CHX, with or without MG132, for the
indicated times. In each case, the level of DsRed was used as an internal control. Protein levels were assessed by immunoblot analysis. Error bars
represent ± SD.
(B) Sequence analysis of the C-terminal region of Pax3 (and corresponding region of Pax7) replaced in Pax3FKHR by the FKHR activation domain.
Lysines 475 and 437 of Pax3 are in bold and underlined.
(C) Analysis of Pax3 mutant proteins by pulse-chase in myoblasts. Cells were transfected with constructs expressing Pax3, Pax3SM, or Pax3DM, to-
gether with DsRed expression constructs. The cells were then treated with CHX, with or without MG132, for the indicated times. The level of DsRed
was used as an internal control. Error bars represent ± SD.resistance of the proteins to monoubiquitination paralleled
their relative stabilities (compare Figures 4A and 3C).
To assess quantitatively the level of monoubiquitination
of the immunoprecipitated protein, lysates were subjected
to Nickel-agarose pull-down to purify ubiquitinated
proteins using a histidine-tagged ubiquitin. Immunoblot-ting of purified proteins revealed single bands corre-
sponding to monoubiquitinated conjugates (Figure 4B).
By contrast, identical analysis of p21CIP1 revealed multi-
ple, high-molecular-weight polyubiquitinated conjugates
(Figures S5A and S5B). Quantitation of the level of
monoubiquitination of the different forms of Pax3 againCell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 353
Figure 4. Correlation between the Level of Monoubiquitination and the Rate of Degradation of Pax3 Proteins
For (C) and (E), representative results are presented above and quantitative analyses of replicate experiments are shown below.
(A) Analysis of the level of ubiquitination of WT and mutant Pax3 proteins in vivo. Myoblasts transfected with Pax3-GFP, Pax3SM-GFP, or Pax3DM-GFP
expression constructs were treated for 6 hr with MG132 and lysed. Proteins were denatured by boiling and analyzed by immunoblotting using anti-
GFP (for Pax3 proteins), FK-1 (recognizes only polyubiquitinated proteins), and FK-2 (recognizes polyubiquitinated and monoubiquitinated proteins)
antibodies. Arrows show the positions of Pax3 proteins and monoubiquitinated Pax3 proteins (Pax3-Ub1) and where any polyubiquitinated Pax3
proteins (Pax3-Ubn) would migrate if present.
(B) Analysis of the level of monoubiquitination of WT and mutant Pax3 proteins in vivo. Myoblasts transfected with Pax3-GFP, Pax3SM-GFP, or
Pax3DM-GFP expression constructs together with a His6-tagged ubiquitin expression construct were treated with MG132 for 6 hr. His6-tagged ubiq-
uitin conjugates were purified on Nickel-agarose gels and the migration of Pax3 proteins was analyzed by immunoblotting with an anti-GFP antibody.
Again, arrows show the positions of monoubiquitinated Pax3 proteins (Pax3-Ub1) and where any polyubiquitinated Pax3 proteins (Pax3-Ubn) would
migrate if present. All proteins appeared to be monoubiquitinated, and monoubiquitination levels (shown quantitatively to the right) were determined
as the ratio of monoubiquitinated Pax protein to Pax protein input and then normalized to the value obtained for WT Pax3. Error bars represent ± SD.
(C) Degradation of monoubiquitin (UbK0) fusion proteins of Pax3 mutants. Myoblasts transfected with Pax3SM-UbK0, and Pax3DM-UbK0 expression
constructs were treated with CHX, with or without MG132, for the indicated times, with DsRed as an internal control. Proteins were analyzed by
immunoblotting using anti-Hemaglutinin (HA) and anti-DsRed antibodies. Error bars represent ± SD.
(D) Sequence analysis of the C-terminal region of Pax7 and corresponding region of Pax7 replaced in Pax3FKHR by the FKHR activation domain.
Alanine 468 of Pax7 corresponding to Lysine 475 of Pax3 is indicated in bold and underlined. Alanine 468 is mutated to a lysine in the Pax7A468K
mutant.354 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.
showed that Pax3SM was monoubiquitinated to a lesser
extent than was Pax3, and that Pax3DM was monoubiqui-
tinated even less (Figure 4B).
As a test of the sufficiency of monoubiquitination to drive
Pax3 degradation, the stability of each of the Pax3 mutants
was assessed when expressed as fusion proteins with
UbK0, a modification that does not render protein suscep-
tible to proteasomal degradation nonspecifically (Li et al.,
2003). Both Pax3SM-UbK0 and Pax3DM-UbK0 were much
more susceptible to proteasome-mediated degradation
than were the unconjugated forms (Figure 4C), supporting
the hypothesis that monoubiquitination is sufficient to
mediate the degradation of Pax3 proteins.
Lysine 475 Is a Key Residue Representing
the Divergent Signature of Protein Stability
between Pax3 and Pax7
To examine further whether the difference of a single
lysine residue was sufficient to explain the observed differ-
ences between Pax3 and Pax7, we introduced a lysine
into Pax7 at the residue corresponding to lysine 475 in
Pax3 to generate a Pax7A468K mutant (Figure 4D). Unlike
WT Pax7, Pax7A468K was susceptible to proteasomal
degradation with similar kinetics as seen for Pax3
(Figure 4E). Furthermore, analysis of the ubiquitination
status of Pax7A468K revealed that the protein, like Pax3,
became monoubiquitinated in vivo (Figure 4F). These
results confirm that lysine 475 is a key residue that distin-
guishes Pax3 from Pax7 and underline differences in
these two otherwise highly homologous proteins in terms
of protein stability.
Monoubiquitinated Pax3 Associates
with the Proteasome
Proteasomal degradation generally requires polymeric
chains of at least four ubiquitins to allow recognition of
the substrate by the proteasome through an array of ubiq-
uitin receptor proteins such as the intrinsic receptor S5a
(Thrower et al., 2000) or substrate receptors such as
Rad23 (Elsasser and Finley, 2005). To determine the
mechanism by which monoubiquitinated Pax3 is recog-
nized by the proteasome, we first tested for an association
between S5a and Pax3 using a pull-down assay, again
using p21CIP1 as a positive control (Figure S6). We were
able to pull down Pax3 with S5a protein (Figure 5A). Iden-
tical studies with the Pax3 mutants, Pax3SM and Pax3DM,
revealed that the relative levels of these proteins thatcould be pulled down with S5a directly correlated with
their respective levels of monoubiquitination and protein
degradation (Figures 3C, 4A, and 4B).
Since S5a binds selectively to polyubiquitinated pro-
teins (Deveraux et al., 1994; Young et al., 1998), we looked
for a protein that could bridge S5a and monoubiquitinated
Pax3. Given the ability of members of the Rad23 family
both to bind monoubiquitin and to shuttle ubiquitinated
proteins to the proteasome (Bertolaet et al., 2001; Wilkin-
son et al., 2001), we tested members of this family as
potential mediators of the association of monoubiquiti-
nated Pax3 with S5a. Consistent with previous studies
(Hiyama et al., 1999), Rad23A and Rad23B were pulled
down with S5a protein (Figure 5A). Interestingly, the
amounts of Rad23B, but not Rad23A, that were detected
declined in parallel with the amount of Pax3 protein pulled
down (Figure 5A), suggesting an obligate Pax3 Rad23B
binding for association with the proteasome. We also
determined whether Pax3 could be pulled down with the
ubiquitin-association domain 2 (UBA2) of Rad23B. The
relative amount of Pax3 proteins pulled down using the
Rad23B UBA2 domain was in the order Pax3 > Pax3SM
> Pax3DM (Figure 5B). These data further support a model
of Pax3 being targeted to the proteasome by interactions
with Rad23B.
We produced recombinant Pax3 and Pax3-Ub proteins
and performed in vitro binding assays in order to test the
binding between forms of Pax3 and proteins containing
UBA domains. Neither Pax3 nor Pax3-Ub bound directly
to either S5a or Rad23A, but Pax3-Ub bound to Rad23B
(Figure 5C). In addition, Pax3 bound weakly and Pax3-
Ub bound strongly to the UBA2 domain of Rad23B
(Figure 5C), suggesting that the Rad23B Pax3 interface in-
volves not only the ubiquitin moiety but also the Pax3 pro-
tein itself. These data demonstrate the importance and
specificity of Rad23B for the interaction of monoubiquiti-
nated Pax3 with the proteasome.
As an independent test of the hypothesis that the
monoubiquitinated form of Pax3 is the primary form that
is targeted to the proteasome, we transfected myoblasts
with a Pax3 expression construct, performed immunopre-
cipitation of Pax3 after S5a pull-down, and analyzed the
ubiquitination status of the immunoprecipitated Pax3
protein. In cell extracts, a small fraction of the protein
was monoubiquitinated and, again, no polyubiquitination
could be detected (Figure 5D). However, if that extract
was first subjected to S5a pull-down, then virtually all of(E) Analysis of Pax7 mutant protein by pulse-chase in myoblasts. Cells were transfected with a construct expressing Pax7A468K together with a DsRed
expression construct. The cells were then treated with CHX, with or without MG132, for the indicated times. The level of DsRed was used as an
internal control. Error bars represent ± SD.
(F) Analysis of the level of ubiquitination of Pax7A469K protein in vivo. (Left panel) Myoblasts transfected with Pax7-GFP or Pax7A468K-GFP expression
constructs were treated for 6 hr with MG132 and lysed. Proteins were denatured by boiling and analyzed by immunoblotting using anti-GFP (for Pax7
proteins) and FK-2 (recognizes polyubiquitinated and monoubiquitinated proteins) antibodies. Arrows show the positions of Pax7 and monoubiquiti-
nated Pax7 (Pax7-Ub1). (Right panel) Myoblasts transfected with Pax7-GFP or Pax7
A468K-GFP expression constructs together with a His6-tagged
ubiquitin expression construct were treated with MG132 for 6 hr. His6-tagged ubiquitin conjugates were purified on Nickel-agarose gels and the
migration of Pax7 proteins was analyzed by immunoblotting with an anti-GFP antibody. Again, arrows show the positions of Pax7 and monoubiquiti-
nated Pax7 proteins (Pax7-Ub1). Pax7
A468K proteins appeared to be monoubiquitinated.Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 355
Figure 5. Rad23B Is Required for the Binding of Monoubiqui-
tinated Pax3 Protein to the Proteasome
(A) Pax3 pull-down with the proteasomal protein S5a. Myoblasts
transfected with Pax3-GFP, Pax3SM-GFP, or Pax3DM-GFP expression
constructs were treated with MG132 for 6 hr. Cell extracts were sub-
jected to S5a-agarose pull-down and levels of Pax3, Rad23A, and
Rad23B proteins were analyzed by immunoblotting with anti-GFP,356 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.the immunoprecipitated Pax3 was monoubiquitinated
(Figure 5D). Therefore, Pax3 proteins that bind to the pro-
teasome are monoubiquitinated, further suggesting that
monoubiquitination of Pax3 is required for its degradation
by the proteasome.
Since S5a exists in both proteasome-bound and free
forms (van Nocker et al., 1996), we assessed whether
the Pax3/Rad23B/S5a complex could be copurified with
the 26S proteasome. After transfecting myoblasts with
Pax3 constructs, we immunoprecipitated the proteasome
using a polyclonal antibody directed against the ‘‘core’’
20S proteasome subunits. Rad23B coprecipitated with
the proteasome core, with higher levels associated with
the proteasome in Pax3-transfected cells compared to
controls (Figure 5E). In addition, only one form of Pax3
could be detected in association with the proteasome,
and this form corresponded to monoubiquitinated Pax3
by molecular weight. These results demonstrate the pres-
ence of the trimeric protein complex of S5a/Rad23B/
Pax3-Ub in a proteasomal context.
anti-Rad23A, and anti-Rad23B antibodies. Pax3 protein levels (shown
quantitatively on the right) were determined as the ratio of Pax protein
pulled down to Pax protein input and then normalized to the value
obtained for WT Pax3. Error bars represent ± SD.
(B) Pax3 coimmunoprecipitates with Rad23B ubiquitin-associated
domain 2 (UBA2). Myoblasts transfected with Pax3-GFP, Pax3SM-
GFP, or Pax3DM-GFP expression construct were treated with MG132
for 6 hr. Cell extracts were subjected to Rad23B (UBA2)-agarose
pull-down and levels of Pax3 proteins were analyzed by immunoblot-
ting with anti-GFP antibody. Pax3 protein levels were determined as
the ratio of Pax protein pulled down to Pax protein input relative to
Pax3. Error bars represent ± SD.
(C) Binding studies between Pax3 or Pax3-Ub and S5a, Rad23A,
Rad23B, or Rad23B UBA2. Pax3, Pax3-Ub, Rad23A, and Rad23B
were produced as GST fusion proteins. Proteins were purified with
glutathione sepharose beads. GST tags of Pax3 and Pax3-Ub were
removed by Thrombin treatment. S5a, Rad23A, Rad23B, and
Rad23B UBA2-agarose beads were mixed in lysis buffer with Pax3
or Pax3-Ub and washed, and Pax3 proteins were analyzed by immu-
noblots with anti-Pax3 antibody.
(D) Analysis of the ubiquitination status of Pax3 bound to the proteaso-
mal protein S5a. Myoblasts transfected with a Pax3-GFP expression
construct were treated with MG132 for 6 hr. Cell extracts were
subjected to S5a-agarose pull-down. The resulting purified proteins
were then denatured by boiling and subjected to immunoprecipitation
with a GFP antibody. As a control, cell extracts were directly denatured
and immunoprecipitation with the GFP antibody was conducted.
Proteins were analyzed by immunoblotting with anti-GFP and anti-
ubiquitin (FK-2) antibodies. Arrows indicate the positions of Pax3
and monoubiquitinated Pax3 protein.
(E) Immunoprecipitation of the 26S proteasome. Myoblasts trans-
fected with GFP or Pax3-GFP expression constructs were treated
with MG132 for 6 hr. Cell extracts were subjected to immunoprecipita-
tion with a 20S core protein antibody. Proteins were analyzed by
immunoblotting with an anti-GFP antibody (Pax3), anti-Rad23B
antibody (Rad23B), anti-S5a antibody (S5a), anti-S8/Rpt6 antibody
(S8), and anti-20S core antibody (20S Core). In control and Pax3-trans-
fected cells, the same amount of 20S proteasome subunits were pulled
down as shown with the 20S core antibody. The presence of the 19S
proteasome was assessed by the presence of S8/Rpt6 and S5a
proteins. Detected Pax3 protein displays a molecular weight consis-
tent with a monoubiquitinated form (arrow).
Figure 6. Rad23B Is Required for the Binding of Pax3 to the Proteasome
(A) Wild-type (WT), RAD23A/, Rad23B/, and DKO MEFs were transfected with a Pax3-GFP expression construct and treated with MG132 for 6 hr.
Cell extracts were subjected to S5a-agarose pull-down and levels of Pax3 proteins were analyzed by immunoblotting with an anti-GFP antibody.
(B) Rad23B is required for Pax3 degradation. Pax3 protein stability was analyzed by pulse-chase in MEFs that were transfected with Pax3 together
with DsRed expression constructs and treated with CHX for the indicated times. In each case, transfection of DsRed was used as an internal control.
Protein stability was assessed by immunoblot analysis. Representative results are shown above and quantitative analyses of replicate studies are
shown below. Error bars represent ± SD.Rad23B Is Required for Pax3 Association
with and Degradation by the Proteasome
To further test the importance of Rad23B for the associa-
tion of Pax3 with the proteasome, we assessed the bind-
ing of Pax3 to S5a in cells with aberrant patterns of
expression of Rad23 isoforms. For these studies, we
used WT mouse embryonic fibroblasts (MEFs) or MEFS
deficient in Rad23A, Rad23B, or both isoforms (‘‘double
knockout’’ [DKO]). MEFs were transfected with Pax3
constructs, and extracts were subjected to S5a pull-
down assays. Pax3 proteins could be pulled down only
in cells expressing Rad23B (Figure 6A). No Pax3 was de-
tected in the Rad23B/ or DKO cells. In addition, when
we assessed the stability of Pax3 proteins in these differ-
ent cells, Pax3 was degraded only in the cells expressing
Rad23B (Figure 6B). Overall, these results show that
Rad23B plays an essential role in shuttling Pax3 to the
proteasome to mediate its degradation.
Functional Significance of the Regulation
of Pax3 Stability
Since Pax3 is known to inhibit myogenic terminal differen-
tiation in C2C12 (Epstein et al., 1995), we hypothesized
that the degradation of Pax3 is important for the progres-
sion of the myogenic program beyond commitment. To
test this hypothesis, we examined the effects of the
expression for Pax3 proteins with differential susceptibility
to proteasomal degradation (Pax3, Pax3SM, or Pax3DM) on
the differentiation of primary myoblasts. Transfection
efficiencies and the levels of expression were similar for
all constructs (Figures S7A and S7B). After 48 hr, whenPax3 proteins had degraded according to their respective
protein stability (Figure S7C), we induced differentiation
for 24 hr. Compared to control cultures, cultures of cells
expressing Pax3 proteins showed a marked delay in
fusion, with the more stable forms of Pax3 (Pax3DM and
Pax3SM) having the largest effect (Figure 7A). The inhibi-
tion of fusion was paralleled by a reduction in expression
of markers of terminal myogenic differentiation (Figure 7B).
Interestingly, when examined by immunofluorescence,
the expression patterns of Myosin Heavy Chain and a-
Actinin were mutually exclusive with Pax3 (Figures 7C
and S7D), suggesting that the expression of Pax3 main-
tains myogenic progenitors in an undifferentiated state
and that the degradation of Pax3 is essential for myogenic
differentiation to occur.
DISCUSSION
Previous results suggested that Pax3 is transiently
expressed during satellite cell activation ex vivo and
that Pax3 expression corresponded to a highly prolifera-
tive state of pre-myoblast cells (Conboy and Rando,
2002). This report adds to these results by demonstrating
that after the peak of protein expression, Pax3 protein
level is downregulated as the cells become committed
myoblasts and that a further decline is necessary for
terminal myogenic differentiation, consistent with previ-
ous findings (Epstein et al., 1995). Similar to the process
of melanocyte stem cell differentiation (Lang et al., 2005),
Pax3 protein expression seems to be associated with an
intermediate precursor cell of the myogenic lineage.Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 357
Figure 7. Functional Significance of the
Regulation of Pax3 Stability
(A) Primary myoblasts were transfected with
GFP, Pax3-GFP, Pax3SM-GFP, and Pax3DM-
GFP expression constructs and switched to
differentiation medium 48 hr post-transfection
for 24 hr. Representative phase-contrast
(above) and GFP fluorescence (below) images
are shown. Arrows indicate mononucleated
cells expressing Pax3 fusion proteins and
arrowheads indicate mononucleated cells
negative for Pax3 fusion protein expression.
Percentages shown represent the percentages
of mononucleated cells in three different
experiments.
(B) Analysis of the level of expression of
myogenic differentiation markers. Primary
myoblasts were transfected with GFP, Pax3-
GFP, Pax3SM-GFP, and Pax3DM-GFP express-
ing constructs and switched to differentiation
medium 48 hr post-transfection for 24 hr. Cells
were harvested and analyzed by immunoblot
with anti-GFP (GFP and Pax3 proteins), anti-
Myogenin (MyoG), anti-Sarcomeric a-Actinin,
anti-Myosin Heavy Chain (MyHC), and anti-
GAPDH. GFP protein (asterisk) migrates to
a different level than the Pax3-GFP proteins
but is shown at the same position here to
compare expression levels.
(C) Immunofluorescence of primary myoblasts
transfected with GFP, Pax3-GFP, Pax3SM-
GFP, and Pax3DM-GFP expression constructs
and switched to differentiation medium 48 hr
after transfection for 24 hr. Cells were fixed
and stained with antibody against MyHC
(Cy3) and counterstained for nuclei with DAPI,
whereas GFP fluorescence was detected
directly.During development, Pax3 is expressed as in myogenic
progenitors, and overexpression of Pax3 promotes
myogenic commitment of cells in the presomitic paraxial
and lateral plate mesoderm (Maroto et al., 1997). These
Pax3-induced progenitors also expressed markers of
myogenic differentiation after 5 days in culture, although
neither the levels of Pax3 protein nor the uniformity of dif-
ferentiation were examined (Maroto et al., 1997). There-
fore, Pax3 expression is clearly associated with a highly
proliferative undifferentiated progenitor population during
development as well, but the regulatory mechanisms that
lead to differentiation of Pax3+ cells (including the358 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.possible degradation of Pax3 protein) remain to be
determined.
Genetic studies using reporter genes suggest that Pax3
is expressed in a subset of quiescent satellite cells (Relaix
et al., 2006), whereas it appears that the majority of
satellite cells express only Pax7 (Seale et al., 2000).
Pax3 and Pax7 share a very high degree of homology
and both are expressed in the myogenic lineage, but
they differ both in terms of their patterns of expression
and their functionality (Relaix et al., 2004, 2006). While
considerable attention has been directed to patterns of
expression through knockin and transgenic studies, which
only examine transcriptional regulation, no studies have
investigated posttranscriptional regulation that might
explain different patterns of expression of Pax3 and
Pax7 at the protein level.
The results of the present study demonstrate an impor-
tant difference between Pax3 and Pax7 regulation at the
level of protein stability. The levels of Pax 3 protein are
regulated by ubiquitination and proteasomal degradation,
whereas levels of Pax7 protein are not. Remarkably, one
amino acid (lysine 475) at the C-terminal region of Pax3
appears to be a critical residue, rendering Pax3 suscepti-
ble to ubiquitination and subsequent proteasomal degra-
dation. In Pax7, this residue is an alanine and thus not
a target for ubiquitination. However, when this alanine is
changed to a lysine, Pax7 becomes susceptible to ubiqui-
tination and proteasomal degradation, further emphasiz-
ing the critical importance of lysine 475 for the susceptibil-
ity of Pax3 to proteasome degradation. Another lysine in
the C-terminal region of Pax3 (lysine 437), which is present
also in Pax7, appears also to be important for Pax3 ubiq-
uitination since the mutation of this residue enhances the
stability of Pax3 in vivo and in vitro. Furthermore, it is
intriguing that while both lysines are critical for Pax3
protein stability, the species detected indicated ubiquiti-
nation at only a single residue. However, this is precisely
what was observed in initial studies of protein ubiquitina-
tion as degradation signals. Chau et al. demonstrated
that only two of the 22 lysines in the b-galactosidase pro-
tein were targets for polyubiquitination, and that the ubiq-
uitin conjugation at one lysine precluded ubiquitination of
the other lysine (Chau et al., 1989). The ubiquitination of
Pax3 could be subject to the same constraints. Lysine
475 or lysine 437 may both be targets for ubiquitination,
but the ubiquitination of one may possibly preclude ubiq-
uitination of the other. In fact, the differential patterns of
Pax3 and Pax7 ubiquitination likely conform to the
N-end rule (Varshavsky, 1997), in which the minimal
requirements for substrate ubiquitination are an appropri-
ate recognition determinant (a ‘‘destabilization signal’’)
and a sterically accessible lysine. Accordingly, the rele-
vant ubiquitin-conjugating enzyme might recognize the
critical determinant and the sterically accessible lysine of
Pax3, but comparable combinations do not exist in
Pax7, as the ubiquitination depends stringently upon the
spatial proximity of the destabilizing signal and the mobil-
ity of the region containing the lysine (Bachmair and
Varshavsky, 1989).
In addition to the intriguing finding that Pax3, but not
Pax7, is regulated by ubiquitination is the even more unex-
pected set of results suggesting that it is a monoubiquiti-
nated form of Pax3 that is targeted for proteasomal degra-
dation. Monoubiquitination is known to target membrane
proteins for endocytosis and lysosomal degradation or
to be a posttranslational modification that is involved in
transcriptional regulation (Hicke, 2001). Monoubiquitina-
tion of p53 protein is interpreted as a nuclear export signal
(Li et al., 2003). Heretofore, there have been no reports of
monoubiquitination being a signal for proteasomal degra-dation. However, although polyubiquitination of a target
protein allows for efficient recognition by the proteasome
and subsequent destruction (Thrower et al., 2000), locali-
zation of a protein to the proteasome, even independent of
ubiquitination, is sufficient to permit proteasomal degra-
dation (Janse et al., 2004). For example, ornithine decar-
boxylase is degraded by the proteasome without ubiquiti-
nation (Coffino, 2001). Thus, a mechanism that facilitates
shuttling or efficient binding of a protein to a proteasomal
subunit appears to be sufficient to target a protein for pro-
teasomal degradation. Our results are consistent with
a model whereby monoubiquitinated Pax3, but not nonu-
biquitinated Pax3, is targeted to the proteasome for
degradation in a process mediated by binding of monou-
biquitinated Pax3 to S5a via Rad23B (Figure S8). We
cannot rule out the possibility that some low levels of poly-
ubiquitinated forms are generated in vivo and rapidly
degraded. However, under every experimental condition
tested, nonubiquitinated and monoubiquitinated forms
of Pax3 were clearly present, easily detected, and the
predominant species.
Many ubiquitin-binding proteins have been identified
and each of them displays ubiquitin-binding domains
(UBDs) that are structurally diverse (Hicke et al., 2005).
UBDs can interact directly with monoubiquitin and/or
polyubiquitin chains. These different ubiquitin receptors
exhibit a remarkable specificity for their polyubiquitinated
proteins (Verma et al., 2004), and therefore these recep-
tors constitute an important aspect of substrate selectivity
of the UPS. Our data suggest that ubiquitin-binding
proteins may also bind to monoubiquitinated proteins
and mediate their binding to the proteasome for degrada-
tion. Monoubiquitinated Pax3 does not bind to S5a
directly but rather indirectly via Rad23B. Interestingly,
we show that Rad23B, but not Rad23A, binds monoubi-
quitinated Pax3, demonstrating a clear specificity for the
substrate between the two Rad23 isoforms. Although
Rad23B UBA2 also binds to nonubiquitinated Pax3 (al-
though less strongly than to monoubiquitinated Pax3),
only monoubiquitinated Pax3 binds to full-length
Rad23B and is associated with the proteasome. These re-
sults suggest that the interaction between Pax3 and
Rad23B alone is not sufficient and requires the presence
of the ubiquitin to strengthen the interaction and promote
targeting to the proteasome. As Rad23B has also been
shown to have a weak interaction with ubiquitin monomer
(Raasi et al., 2004), it is possible that it is the combination
of binding to Pax3 and ubiquitin that mediates the target-
ing of monoubiquitinated Pax3 to the proteasome by
Rad23B.
We were unable to detect any polyubiquitination of
Pax3 under any in vivo or in vitro conditions. Polyubiquiti-
nation requires E1, E2, and E3 ubiquitin ligases, whereas
monoubiquitination of proteins requires E1 and E2 activi-
ties only (Ciechanover et al., 2000). The molecular mech-
anism leading to the monoubiquitination of Pax3 remains
unknown. It may involve only E1 or E2 ubiquitin ligases.
However, as Rad23B is a negative regulator ofCell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 359
polyubiquitin chain formation (Ortolan et al., 2000), Pax3
ubiquitination may involve E1, E2, and E3 ubiquitin ligases
with Rad23B preventing the formation of a polyubiquitin
chain. Thus, Rad23B might be important not only to bring
monoubiquitinated Pax3 to the proteasome but also to
regulate the ubiquitination reaction.
In summary, our results add to the growing list of the
pleiotropic effects of ubiquitination of regulating protein
stability and suggest that monoubiquitination of a protein
may be a signal for proteasomal degradation. The mech-
anism described here for regulating Pax3 protein levels
is likely to underlie differences in the patterns of expres-
sion between Pax3 and Pax7. These results provide new
insights as to the molecular mechanisms regulating
Pax3 in muscle stem cells and might also shed light on
the regulation of Pax proteins in other stem cell lineages.
EXPERIMENTAL PROCEDURES
Details about cDNA cloning and constructs and about standard
methodologies (immunofluorescence microscopy, immunoblotting,
immunoprecipitation, FACS, quantitative RT-PCR) can be found in
the Supplemental Data available with this article online.
Constructs and Cell Lines
The ts20b and H38.5 cell lines were provided by Dr. H.L. Ozer (UMDNJ),
the Pax3FKHR and Pax7FKHR mammalian expression constructs
were provided by Dr. F. Barr (U. Penn), the UbK0 and Ub mammalian ex-
pression constructs were provided by Dr. W. Gu (Columbia University),
and the His6-tagged ubiquitin mammalian expression vector was pro-
vided by Dr. D. Bohmann (University of Rochester). WT, Rad23A/,
Rad23B/, and DKO MEFs were provided by Dr. Jan H.J. Hoeijmakers
(Erasmus Medical Center). pGEX-hHR23A was provided by Dr. K.J.
Walters (University of Minnesota). pGEX-mHR23B was provided by
Dr. W.J. Lennarz (Stony Brook university).
Satellite Cell Isolation, Myoblast Cultures, and Single-Fiber
Isolations
Satellite cells were purified from bulk fibers and activated in vitro as de-
scribed previously (Conboy and Rando, 2002; Conboy et al., 2003).
Myoblast cultures were maintained as proliferating mononucleated
cells or were induced to differentiate as previously described (Quach
and Rando, 2006). Single myofibers and associated satellite cells
from extensor digitorum longus muscles were prepared as described
previously (Rosenblatt et al., 1995).
In Vivo Protein Stability Assay
C2C12 myoblasts were transfected with pEGFP-N3-Pax3, pcDNA3.1-
Pax3FKHR, pEGFP-N3-Pax3SM, pEGFP-N3-Pax3DM, pEGFP-N3-
Pax7, and pEGFP-N3-Pax7A468K plasmids with pDsRed2-N1 plasmid
as a control. Cycloheximide (CHX) (5 mM) and either dimethylsulfoxide
(DMSO) or MG132 (10 mM) were added 24 hr after transfection, cells
were harvested at each time point (0, 6, 12, and 24 hr), and lysates
were analyzed by Western blots. The ts20b and H38-5 cells were
used in the same way except that they were transfected with only
pEGFP-N3-Pax3 and pDsRed2-N1 expression vectors. Cells were
treated with CHX and placed at 34C or 40C. MEFs were transfected
with pEGFP-N3-Pax3 and pDsRed2-N1 and were treated with CHX.
Primary myoblasts were treated with DMSO or MG132 (5, 7.5, or 10
mM) for 6 hr. Cells were harvested and lysates were analyzed by West-
ern blots. The films were scanned and quantified with ImageJ (http://
rsb.info.nih.gov/ij/).360 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.Cell-free Coupled Ubiquitination/Degradation
and Ubiquitination Assays
Coupled ubiquitination/degradation assays were performed on Pax
and p21CIP1 proteins produced with Promega TNT quick coupled tran-
scription/translation system. The reaction mix contained 2 ml of in vitro-
labeled [35S] Pax and p21CIP1 protein and 2 ml of a 53 stock reaction
mix (50 mM Tris-HCl pH 7.6, 5 mM MgCl2, 2 mM ATP, 10 mM phospho-
creatine, 17.5 U/ml phosphocreatine kinase, 1 mM ubiquitin aldehyde,
0.8 mg ubiquitin-conjugating enzyme fractions [Sigma], and 50 nM 26S
proteasome [Biomol International]). Following incubation at 30C for 0,
1, 2, 4, and 6 hr, reactions were stopped by addition of sample buffer
and subjected to SDS-PAGE followed by autoradiography. Ubiquitina-
tion assays were performed in the same way at 37C in the presence of
MG132 either with Ub or UbK0 (Boston Biochem) and without 26S
proteasome. In the case of proteasomal pretreatment, the reaction
mix without labeled Pax3 proteins was incubated for 6 hr at 37C. After
treatment, 10 mM MG132 and 10 ml of in vitro-labeled [35S] Pax protein
were added to the reaction mix and incubated at 37C. Ubiquitin-
conjugating enzyme fractions (Sigma) were pretreated with 1 mg of
Ub or UbK0 (Boston Biochem) in reaction mix (50 mM Tris-Cl pH 7.6,
5 mM MgCl2, 2 mM ATP, 10 mM phosphocreatine, 17.5 U/ml phospho-
creatine kinase), 1 mM ubiquitin aldehyde, and 50 nM 26S proteasome
(Biomol International) at 37C for 4 hr. Recombinant Pax3 protein,
25 mg of Ub, and 26S proteasome were added and incubated at
37C for 6 and 18 hr. Reactions were stopped by addition of sample
buffer and subjected to SDS-PAGE followed by transfer and Western
blot analysis.
In Vivo Ubiquitination
Myoblasts were transfected as described above with pEGFP-N3-
Pax3, pEGFP-N3- Pax3SM, pEGFP-N3- Pax3DM, pEGFP-N3-Pax7, or
pEGFP-N3-Pax7A468K constructs alone or with His6-tagged ubiquitin
construct. Transfected cells were pretreated with 10 mM MG132 for
6 hr to block Pax3 degradation, and extracts were prepared in lysis
buffer containing 100 mM MG132, 20 mM ubiquitin aldehyde, and
100 mM N-ethylmaleimide (NEM, Sigma). Lysates were denatured by
boiling for 5 min in the presence of 0.1% SDS. Immunoprecipitation
was carried out by adding 10 mg of anti-GFP monoclonal antibody
(Santa Cruz Biotechnology). For cotransfection of the Pax3 and His6-
tagged ubiquitin expression vectors, cells were treated with 10 mM
MG132 for 6 hr and extracts were prepared in CelLytic M reagent
(Sigma) lysis buffer containing 100 mM MG132, 20 mM ubiquitin alde-
hyde. His-tagged proteins were purified on Nickel affinity gel using
His-Select M affinity Capture Kit (Sigma) according to the manufac-
turer’s instructions. Immunoprecipitated and purified proteins were
analyzed by Western blotting using an anti-GFP monoclonal antibody
and anti-ubiquitin antibodies (FK-1 and FK-2).
S5a and Rad23 Pull-Down Assays
Myoblasts were transfected as described above with pEGFP-N3-
Pax3, pEGFP-N3-Pax3SM, or pEGFP-N3-Pax3DM constructs. MEFs
were transfected with pEGFP-N3-Pax3. Transfected cells were pre-
treated with 10 mM MG132 for 6 hr to block protein degradation and
extracts were prepared in lysis buffer containing 100 mM MG132,
20 mM ubiquitin aldehyde, and 100 mM NEM. Pull-down was carried
out by adding 10 ml of Agarose S5a or Agarose Rad23B UBA2 (Biomol
International). After S5a pull-down, the beads were washed three
times, resuspended in lysis buffer containing 0.1% SDS, and dena-
tured by boiling for 5 min.
Recombinant Proteins and In Vitro Protein-Binding Assay
Recombinant Pax3, Pax3-UbWT, Rad23A, and Rad23B were produced
as GST-fusion proteins in E. coli BL21, extracted in MT-PBS (10%
glycerol, 1 mM DTT, 0.5 mM PMSF) containing 1% Triton X-100, and
purified on glutathione-Sepharose resin (GE). GST tags were excised
with Thrombin (GE) and PreScission (GE) (5 U/ml for 6 hr at room
temperature). S5a protein and Rad23B UBA2 beads (10 ml) were
incubated with the same amount of Pax3 and Pax3-Ub protein product
at room temperature for 1 hr in lysis buffer used for S5a pull-down with
cell lysates. In the case of Rad23A and Rad23B pull-down, GST fusion
proteins were extracted as described above and incubated with the
same amount of Pax3 and Pax3-UbWT. Beads were washed and
bound proteins were eluted with 20 ml of SDS loading buffer.
Supplemental Data
Supplemental Data include additional Experimental Procedures and
eight figures and can be found with this article online at http://www.
cell.com/cgi/content/full/130/2/349/DC1/.
ACKNOWLEDGMENTS
We thank all the members of the Rando laboratory for helpful com-
ments and discussion. We thank Drs. H.L. Ozer, F. Barr, W. Gu, D.
Bohmann, K. Walters, W. Lennarz, and J. Hoeijmakers for reagents.
This work was supported by a Muscular Dystrophy Association Devel-
opment Grant to S.C.B., by grants from the NIH (AG23806), the De-
partment of Veterans Affairs (Merit Review), and the Ellison Medical
Foundation to T.A.R., and by an NIH Director’s Pioneer Award to T.A.R.
Received: September 14, 2006
Revised: March 17, 2007
Accepted: May 17, 2007
Published: July 26, 2007
REFERENCES
Bachmair, A., and Varshavsky, A. (1989). The degradation signal in
a short-lived protein. Cell 56, 1019–1032.
Barr, F.G. (2001). Gene fusions involving PAX and FOX family members
in alveolar rhabdomyosarcoma. Oncogene 20, 5736–5746.
Bennicelli, J.L., Advani, S., Schafer, B.W., and Barr, F.G. (1999). PAX3
and PAX7 exhibit conserved cis-acting transcription repression
domains and utilize a common gain of function mechanism in alveolar
rhabdomyosarcoma. Oncogene 18, 4348–4356.
Bertolaet, B.L., Clarke, D.J., Wolff, M., Watson, M.H., Henze, M., Div-
ita, G., and Reed, S.I. (2001). UBA domains of DNA damage-inducible
proteins interact with ubiquitin. Nat. Struct. Biol. 8, 417–422.
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier,
C. (1995). Essential role for the c-met receptor in the migration of myo-
genic precursor cells into the limb bud. Nature 376, 768–771.
Bloom, J., Amador, V., Bartolini, F., DeMartino, G., and Pagano, M.
(2003). Proteasome-mediated degradation of p21 via N-terminal ubiq-
uitinylation. Cell 115, 71–82.
Bober, E., Franz, T., Arnold, H.H., Gruss, P., and Tremblay, P. (1994).
Pax-3 is required for the development of limb muscles: a possible role
for the migration of dermomyotomal muscle progenitor cells. Develop-
ment 120, 603–612.
Buckingham, M., Bajard, L., Chang, T., Daubas, P., Hadchouel, J.,
Meilhac, S., Montarras, D., Rocancourt, D., and Relaix, F. (2003).
The formation of skeletal muscle: from somite to limb. J. Anat. 202,
59–68.
Chau, V., Tobias, J.W., Bachmair, A., Marriott, D., Ecker, D.J., Gonda,
D.K., and Varshavsky, A. (1989). A multiubiquitin chain is confined to
specific lysine in a targeted short-lived protein. Science 243, 1576–
1583.
Chowdary, D.R., Dermody, J.J., Jha, K.K., and Ozer, H.L. (1994).
Accumulation of p53 in a mutant cell line defective in the ubiquitin path-
way. Mol. Cell. Biol. 14, 1997–2003.
Ciechanover, A., Orian, A., and Schwartz, A.L. (2000). Ubiquitin-medi-
ated proteolysis: biological regulation via destruction. Bioessays 22,
442–451.Coffino, P. (2001). Antizyme, a mediator of ubiquitin-independent
proteasomal degradation. Biochimie 83, 319–323.
Conboy, I.M., and Rando, T.A. (2002). The regulation of Notch signal-
ing controls satellite cell activation and cell fate determination in
postnatal myogenesis. Dev. Cell 3, 397–409.
Conboy, I.M., Conboy, M.J., Smythe, G.M., and Rando, T.A. (2003).
Notch-mediated restoration of regenerative potential to aged muscle.
Science 302, 1575–1577.
Deveraux, Q., Ustrell, V., Pickart, C., and Rechsteiner, M. (1994). A 26
S protease subunit that binds ubiquitin conjugates. J. Biol. Chem. 269,
7059–7061.
Elsasser, S., and Finley, D. (2005). Delivery of ubiquitinated substrates
to protein-unfolding machines. Nat. Cell Biol. 7, 742–749.
Epstein, J.A., Lam, P., Jepeal, L., Maas, R.L., and Shapiro, D.N. (1995).
Pax3 inhibits myogenic differentiation of cultured myoblast cells. J.
Biol. Chem. 270, 11719–11722.
Fujimuro, M., Sawada, H., and Yokosawa, H. (1994). Production and
characterization of monoclonal antibodies specific to multi-ubiquitin
chains of polyubiquitinated proteins. FEBS Lett. 349, 173–180.
Gros, J., Manceau, M., Thome, V., and Marcelle, C. (2005). A common
somitic origin for embryonic muscle progenitors and satellite cells.
Nature 435, 954–958.
Hershko, A., Ganoth, D., Pehrson, J., Palazzo, R.E., and Cohen, L.H.
(1991). Methylated ubiquitin inhibits cyclin degradation in clam embryo
extracts. J. Biol. Chem. 266, 16376–16379.
Hicke, L. (2001). Protein regulation by monoubiquitin. Nat. Rev. Mol.
Cell Biol. 2, 195–201.
Hicke, L., Schubert, H.L., and Hill, C.P. (2005). Ubiquitin-binding
domains. Nat. Rev. Mol. Cell Biol. 6, 610–621.
Hiyama, H., Yokoi, M., Masutani, C., Sugasawa, K., Maekawa, T.,
Tanaka, K., Hoeijmakers, J.H., and Hanaoka, F. (1999). Interaction of
hHR23 with S5a. The ubiquitin-like domain of hHR23 mediates interac-
tion with S5a subunit of 26 S proteasome. J. Biol. Chem. 274, 28019–
28025.
Janse, D.M., Crosas, B., Finley, D., and Church, G.M. (2004). Localiza-
tion to the proteasome is sufficient for degradation. J. Biol. Chem. 279,
21415–21420.
Lang, D., Lu, M.M., Huang, L., Engleka, K.A., Zhang, M., Chu, E.Y.,
Lipner, S., Skoultchi, A., Millar, S.E., and Epstein, J.A. (2005). Pax3
functions at a nodal point in melanocyte stem cell differentiation.
Nature 433, 884–887.
Li, M., Brooks, C.L., Wu-Baer, F., Chen, D., Baer, R., and Gu, W.
(2003). Mono- versus polyubiquitination: differential control of p53
fate by Mdm2. Science 302, 1972–1975.
Maroto, M., Reshef, R., Munsterberg, A.E., Koester, S., Goulding, M.,
and Lassar, A.B. (1997). Ectopic Pax-3 activates MyoD and Myf-5
expression in embryonic mesoderm and neural tissue. Cell 89, 139–
148.
Matsuzaki, H., Daitoku, H., Hatta, M., Tanaka, K., and Fukamizu, A.
(2003). Insulin-induced phosphorylation of FKHR (Foxo1) targets to
proteasomal degradation. Proc. Natl. Acad. Sci. USA 100, 11285–
11290.
Ortolan, T.G., Tongaonkar, P., Lambertson, D., Chen, L., Schauber, C.,
and Madura, K. (2000). The DNA repair protein rad23 is a negative reg-
ulator of multi-ubiquitin chain assembly. Nat. Cell Biol. 2, 601–608.
Quach, N.L., and Rando, T.A. (2006). Focal adhesion kinase is essen-
tial for costamerogenesis in cultured skeletal muscle cells. Dev. Biol.
293, 38–52.
Raasi, S., Orlov, I., Fleming, K.G., and Pickart, C.M. (2004). Binding of
polyubiquitin chains to ubiquitin-associated (UBA) domains of
HHR23A. J. Mol. Biol. 341, 1367–1379.Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc. 361
Relaix, F., Rocancourt, D., Mansouri, A., and Buckingham, M. (2004).
Divergent functions of murine Pax3 and Pax7 in limb muscle develop-
ment. Genes Dev. 18, 1088–1105.
Relaix, F., Rocancourt, D., Mansouri, A., and Buckingham, M. (2005). A
Pax3/Pax7-dependent population of skeletal muscle progenitor cells.
Nature 435, 948–953.
Relaix, F., Montarras, D., Zaffran, S., Gayraud-Morel, B., Rocancourt,
D., Tajbakhsh, S., Mansouri, A., Cumano, A., and Buckingham, M.
(2006). Pax3 and Pax7 have distinct and overlapping functions in adult
muscle progenitor cells. J. Cell Biol. 172, 91–102.
Rosenblatt, J.D., Lunt, A.I., Parry, D.J., and Partridge, T.A. (1995). Cul-
turing satellite cells from living single muscle fiber explants. In Vitro
Cell. Dev. Biol. 31, 773–779.
Seale, P., Sabourin, L.A., Girgis-Gabardo, A., Mansouri, A., Gruss, P.,
and Rudnicki, M.A. (2000). Pax7 is required for the specification of
myogenic satellite cells. Cell 102, 777–786.
Thrower, J.S., Hoffman, L., Rechsteiner, M., and Pickart, C.M. (2000).
Recognition of the polyubiquitin proteolytic signal. EMBO J. 19, 94–
102.362 Cell 130, 349–362, July 27, 2007 ª2007 Elsevier Inc.van Nocker, S., Sadis, S., Rubin, D.M., Glickman, M., Fu, H., Coux, O.,
Wefes, I., Finley, D., and Vierstra, R.D. (1996). The multiubiquitin-
chain-binding protein Mcb1 is a component of the 26S proteasome
in Saccharomyces cerevisiae and plays a nonessential, substrate-spe-
cific role in protein turnover. Mol. Cell. Biol. 16, 6020–6028.
Varshavsky, A. (1997). The N-end rule pathway of protein degradation.
Genes Cells 2, 13–28.
Verma, R., Oania, R., Graumann, J., and Deshaies, R.J. (2004). Multi-
ubiquitin chain receptors define a layer of substrate selectivity in the
ubiquitin-proteasome system. Cell 118, 99–110.
Wilkinson, C.R., Seeger, M., Hartmann-Petersen, R., Stone, M., Wal-
lace, M., Semple, C., and Gordon, C. (2001). Proteins containing the
UBA domain are able to bind to multi-ubiquitin chains. Nat. Cell Biol.
3, 939–943.
Yang, X.M., Vogan, K., Gros, P., and Park, M. (1996). Expression of the
met receptor tyrosine kinase in muscle progenitor cells in somites and
limbs is absent in Splotch mice. Development 122, 2163–2171.
Young, P., Deveraux, Q., Beal, R.E., Pickart, C.M., and Rechsteiner, M.
(1998). Characterization of two polyubiquitin binding sites in the 26 S
protease subunit 5a. J. Biol. Chem. 273, 5461–5467.
